Table 1 Median prior lines of treatment without bridging (min-max)/n = number of patients.

From: T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany

Year

Cilta-cel

Ide-cel

2022

–/(n = 0)

4 (2–8)/(n = 20)

2023

3 (2–4)/(n = 5)

4 (2–10)/(n = 11)

2024 (* as of 30.06.2024)

3 (1–6)/(n = 14)

8 (8–8)/(n = 1)

Total

3 (1–6)/(n = 19)

4 (2–10)/(n = 32)

Back to article page